(CercleFinance.com) – Eli Lilly announced on Monday that it had completed the acquisition of Versanis Bio, a biopharmaceutical company which it had formalized the acquisition last month for an amount of more than 1.9 billion dollars.
The American laboratory specifies that the main candidate of Versanis is bimagrumab, a monoclonal antibody currently being evaluated in the context of a phase 2b study in overweight or obese adults.
Eli Lilly also announced on Monday that it has completed the acquisition of Sigilon Therapeutics, a specialist in encapsulated cell therapies for the treatment of type 1 diabetes.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
